Q-omics provides the consensus-scored DLGAP2 profile across patient tissues and cancer cell-line models. DLGAP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, DLGAP2 is differentially expressed in 17, with the highest sampling consensus in KIRP. Additionally, DLGAP2 RNA expression shows 14,265 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, KIRP, and TGCT as cancer lineages where DLGAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLGAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLGAP2 survival associations across molecular data types. DLGAP2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLGAP2 RNA expression–survival associations across cancer types. High DLGAP2 expression shows unfavorable associations in ACC, but favorable associations in LGG, PAAD, MESO, LUAD and READ. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for DLGAP2 RNA expression.
This table summarizes DLGAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for DLGAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLGAP2 shows lower tumor expression in KIRP, COAD, THCA, HNSC, KIRC and LUAD. The KIRP box plot shows higher DLGAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.813, t-test p < 0.001).
This table shows molecular features associated with DLGAP2 in patient tissues and cancer cell lines. In patient samples, DLGAP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DLGAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
